UCF Scientist Investigates Probiotics as a Potential Treatment for Acid Reflux and Esophageal Cancer
Acid reflux, a pervasive condition characterized by the backward flow of stomach acid into the esophagus, afflicts millions worldwide with symptoms ranging from heartburn and belching to chest discomfort and dysphagia. Beyond these daily discomforts, chronic acid reflux is a known precursor to esophageal cancer, a malignancy with a daunting five-year survival rate hovering around 22%. This grim statistic underscores the urgent need for innovative preventative and therapeutic strategies. Groundbreaking research led by Associate Professor Claudia Andl at the University of Central Florida (UCF) College of Medicine is pioneering a new frontier in the fight against acid reflux and its malignant sequelae by harnessing the potential of probiotics. Probiotics, broadly defined as live microorganisms that confer health benefits to their host, have garnered significant attention in recent years, primarily for their role in enhancing gut health and modulating the digestive microbiome.
Bioengineer